Tyra Biosciences (NASDAQ:TYRA) Stock Rating Lowered by Wall Street Zen

Tyra Biosciences (NASDAQ:TYRA) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Other equities analysts have also issued reports about the stock. Oppenheimer reiterated an “outperform” rating and issued a $36.00 price objective on shares of Tyra Biosciences in a research report on Wednesday, September 10th. Raymond James Financial assumed coverage on shares of Tyra Biosciences in a research note on Tuesday, September 2nd. They set a “strong-buy” rating and a $35.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Wednesday, October 8th. Finally, Wedbush boosted their target price on Tyra Biosciences from $30.00 to $37.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $33.17.

Tyra Biosciences Stock Down 0.3%

Shares of TYRA stock opened at $25.96 on Friday. The stock’s 50-day moving average price is $19.30 and its 200 day moving average price is $14.26. The stock has a market capitalization of $1.39 billion, a PE ratio of -13.88 and a beta of 1.08. Tyra Biosciences has a 52-week low of $6.42 and a 52-week high of $26.34.

Tyra Biosciences (NASDAQ:TYRA) last announced its earnings results on Wednesday, November 5th. The company reported ($0.50) earnings per share for the quarter, meeting the consensus estimate of ($0.50). Analysts expect that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Tyra Biosciences news, Director Robert J. More sold 10,000 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $25.00, for a total transaction of $250,000.00. Following the transaction, the director directly owned 3,823,425 shares in the company, valued at approximately $95,585,625. This represents a 0.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 15.20% of the company’s stock.

Institutional Investors Weigh In On Tyra Biosciences

Several institutional investors have recently modified their holdings of TYRA. Federated Hermes Inc. increased its stake in Tyra Biosciences by 586.3% in the 3rd quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock valued at $30,000 after purchasing an additional 1,841 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Tyra Biosciences by 14.5% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock worth $126,000 after purchasing an additional 1,668 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Tyra Biosciences in the third quarter valued at $133,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Tyra Biosciences in the 2nd quarter worth about $177,000. Finally, Russell Investments Group Ltd. grew its stake in Tyra Biosciences by 27.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company’s stock valued at $178,000 after acquiring an additional 2,766 shares during the last quarter. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.